查看購物車
  • English
封面
市場調查報告書
商品編碼
1912755

幼年特發性關節炎診斷市場（依產品類型、技術及最終用戶分類）－2026-2032年全球預測

Juvenile Idiopathic Arthritis Diagnostic Market by Product Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年幼年特發性關節炎診斷市場價值為 2.3011 億美元，預計到 2026 年將成長至 2.563 億美元，預計到 2032 年將達到 4.7056 億美元，複合年成長率為 10.75%。

關鍵市場統計數據
基準年 2025 2.3011億美元
預計年份：2026年 2.563億美元
預測年份 2032 4.7056億美元
複合年成長率 (%) 10.75%

一個涵蓋診斷挑戰和跨學科必要性的綜合框架，定義了現代檢測和分診幼年特發性關節炎的方法

由於臨床表現型多樣、發炎標記重疊，以及需要及時介入以防止不可逆的關節損傷和發育影響，幼年特發性關節炎的診斷極具挑戰性。早期準確區分少關節型、多關節型和系統性關節炎對於最佳化治療方案、最大限度地減少糖皮質激素暴露以及根據患者獨特的免疫病理特徵制定生物製劑治療方案至關重要。診斷流程越來越依賴綜合方法，將詳細的臨床評估與有針對性的影像學檢查和檢測相結合，從而減少診斷延誤和兒童診療指南的差異。

技術、臨床和監管方面的變革正在共同推動幼年特發性關節炎的診斷朝著更早期、更個人化和更​​實證的方向發展。

由於技術、監管和臨床趨勢的融合，幼年特發性關節炎的診斷格局正在發生變革，這些趨勢提高了診斷準確性和醫療服務的整合性。分子和生物標記主導的策略透過引入能夠區分自體免疫特徵、細胞激素譜和遺傳易感性的檢測組合，減少了對特異性發炎標記物的依賴。同時，影像技術也在不斷發展。高解析度磁振造影（MRI）通訊協定的開發和肌肉骨骼超音波的廣泛應用，使得在最大限度減少輻射暴露的同時，能夠早期發現滑膜炎、腱鞘炎和侵蝕性變化。這些影像技術的進步與自動化判讀工具和影像引導的診斷工作流程相輔相成，縮短了診斷時間，並提高了觀察者間的一致性。

評估2025年美國關稅政策對兒童關節炎診斷的診斷設備、試劑供應鏈和營運籌資策略的影響

2025年美國實施的關稅調整和貿易措施對幼年特發性關節炎診斷所需的診斷設備、試劑和耗材的採購、生產和分銷產生了顯著影響。進口資本設備和特殊試劑關稅的提高給檢查室營運預算帶來了壓力，並可能影響MRI掃描儀、超音波探頭和照護現場設備的採購決策。為此，醫療機構和診斷設備供應商已開始重新評估其供應商組合，優先選擇具有本地生產或區域分銷能力的供應商，以最大限度地減少進口成本波動的影響。

多維度細分洞察揭示了產品類型、技術、最終用戶和檢測方法如何相互關聯，從而驅動診斷選擇和臨床整合。

詳細的細分分析揭示了不同診斷方式和最終用戶之間的交集，從而影響臨床路徑和商業性優先事項。按產品類型評估時，影像診斷和檢查室診斷之間的區別至關重要。影像診斷包括磁振造影（MRI）、超音波和X光等方式，這些方式對於可視化滑膜發炎和結構變化至關重要。另一方面，檢查室診斷包括生物標記檢測、基因檢測和血清學檢測，這些檢測用於檢查免疫特徵和疾病易感性。在生物標記檢測中，諸如急性期蛋白檢測、自體抗體檢測和細胞激素檢測等子類別在特異性和實際效用方面存在差異，這會影響基於臨床症狀和治療目標的檢測選擇。

各地區特定的診斷部署模式和營運重點將影響美洲、歐洲、中東和非洲以及亞太地區的採用率和可近性。

區域趨勢將對三大主要宏觀區域的診斷實務模式、監管參與和供應鏈策略產生重大影響。在美洲，先進的三級醫療中心和社區醫院優先考慮快速、可報銷的診斷方式，這正在塑造臨床應用，推動高解析度成像和檢驗的生物標記檢測的普及，同時要求提供明確的臨床效用證據才能獲得支付方的報銷。對就地檢驗和遠端醫療的過渡性投資正在擴大服務不足地區的醫療覆蓋範圍。同時，採購部門對成本壓力和關稅政策的敏感度正在影響供應商的選擇和合約結構。

診斷創新者如何利用平台差異化、臨床夥伴關係和整合式醫療解決方案來加速應用和臨床檢驗

在幼年特發性關節炎診斷領域，各公司正透過平台創新、臨床夥伴關係和精準的市場推廣策略來實現差異化競爭。診斷設備製造商正在拓展服務模式和臨床支持，以加速影像和照護現場設備的普及應用；而檢測開發人員則優先考慮分析的穩健性、多重檢測能力和臨床檢驗，以證明其在兒童人群中的效用。診斷公司與學術機構之間的策略合作正在加速生物標記的發現，並將基於研究的檢測方法轉化為檢驗的臨床檢測方法。

兒童風濕病診斷開發人員和醫療保健領導者在提高檢驗、供應鏈彈性、完整性和醫療保健協作方面的實際策略重點

產業領導者應優先採取一系列切實可行的措施來改善診斷並鞏固商業性地位。首先，投資進行多學科臨床檢驗研究，將生物標記和影像學結果與治療決策和長期療效聯繫起來，以證明其臨床效用並為醫保報銷談判提供支持。其次，透過供應商多元化、推進關鍵試劑的本地化生產以及建立緊急庫存策略來增強供應鏈韌性，從而減少進口中斷帶來的影響。第三，與兒童風濕病中心和參考實驗室建立策略夥伴關係，以加速產生真實世界證據，並改善各種臨床環境下的檢測流程。

我們採用透明的混合調查方法框架，結合專家訪談、臨床文獻綜合和技術評估，來支持我們的診斷結果和建議。

為確保嚴謹性和相關性，本分析採用結構化的研究途徑，結合與關鍵相關人員的直接對話和系統性的文獻綜述，對證據進行綜合分析。關鍵資訊包括對兒童風濕症醫師、檢查室主任、放射科醫生和供應鏈經理的深入訪談，以了解臨床工作流程、檢驗要求和採購限制。這些定性研究結果與對同行評審的臨床文獻、監管申報文件和技術性能數據的有針對性審查進行三角驗證，以檢驗分析假設並為臨床效用論點提供背景資訊。

整合診斷機會和營運需求，將技術進步轉化為兒童風濕病護理方面可衡量的改進。

總之，在影像技術、生物標記科學和分子診斷技術進步的推動下，幼年特發性關節炎的診斷路徑正朝著更精準、整合和以患者為中心的方向發展。這些進步為縮短診斷延遲、對患者進行分層以進行標靶治療以及改善長期功能預後創造了機會。然而，成功實施這些方法需要協調一致的臨床驗證、穩健的供應鏈策略以及與支付方的積極合作，以確保新的檢驗和平台能夠在不同的醫療機構中得到應用。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的幼年特發性關節炎診斷市場

  • 影像診斷
    • MRI
    • 超音波
    • X光
  • 檢查室診斷
    • 生物標記檢測
      • 急性期蛋白測定
      • 自體抗體檢測
      • 細胞激素測量
    • 基因檢測
    • 血清學檢測

9. 按技術分類的幼年特發性關節炎診斷市場

  • ELISA
  • 流式細胞技術
  • PCR技術

第10章 依最終使用者分類的幼年特發性關節炎診斷市場

  • 診斷檢查室
  • 醫院
  • 研究所
  • 專科診所

第11章 各地區幼年特發性關節炎診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 依組別分類的幼年特發性關節炎診斷市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國幼年特發性關節炎診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章美國青少年特發性關節炎診斷市場

第15章 中國幼年特發性關節炎診斷市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche AG
  • Mayo Clinic
  • Ortho Clinical Diagnostics Holdings plc
  • QIAGEN NV
  • Randox Laboratories Ltd
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB13A79

The Juvenile Idiopathic Arthritis Diagnostic Market was valued at USD 230.11 million in 2025 and is projected to grow to USD 256.30 million in 2026, with a CAGR of 10.75%, reaching USD 470.56 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 230.11 million
Estimated Year [2026] USD 256.30 million
Forecast Year [2032] USD 470.56 million
CAGR (%) 10.75%

Comprehensive framing of diagnostic challenges and multidisciplinary imperatives that define contemporary approaches to juvenile idiopathic arthritis detection and triage

Juvenile idiopathic arthritis presents a complex diagnostic challenge driven by heterogeneous clinical phenotypes, overlapping inflammatory markers, and the need for timely intervention to prevent irreversible joint damage and developmental impacts. Early and accurate differentiation among oligoarticular, polyarticular, and systemic presentations remains central to optimizing therapeutic trajectories, minimizing corticosteroid exposure, and aligning biologic therapies with patient-specific immunopathology. Diagnostic pathways increasingly rely on integrated approaches that combine detailed clinical assessment with targeted imaging and laboratory assays to reduce diagnostic delay and guideline variations across pediatric care settings.

Advances in immunology, molecular genetics, and imaging technology have created opportunities to refine diagnostic criteria and to identify subgroups prone to aggressive disease or extra-articular complications. At the same time, clinical workflows must accommodate evolving assay availability, payer requirements, and specialist referral patterns. Consequently, multidisciplinary coordination between pediatric rheumatologists, radiologists, pathologists, and laboratory medicine teams is vital. This introductory framing sets the stage for deeper analysis of technological innovation, segmentation dynamics, regulatory influences, and operational priorities that shape diagnostic decision-making in contemporary pediatric rheumatology.

How converging technological, clinical, and regulatory shifts are reshaping juvenile idiopathic arthritis diagnostics toward earlier, more personalized, and evidence-driven care

The diagnostic landscape for juvenile idiopathic arthritis is undergoing transformative shifts propelled by converging technological, regulatory, and clinical trends that enhance diagnostic precision and care integration. Molecular and biomarker-driven strategies are reducing reliance on nonspecific inflammatory markers by introducing panels that differentiate autoimmune signatures, cytokine profiles, and genetic predispositions. Concurrently, imaging capabilities have evolved: higher-resolution MRI protocols and the expanded use of musculoskeletal ultrasound enable earlier detection of synovitis, tenosynovitis, and erosive changes while minimizing radiation exposure. These imaging improvements are complemented by automated reading tools and image-guided diagnostic workflows that shorten time to diagnosis and improve inter-rater reliability.

On the technology side, assay platforms such as enzyme-linked immunosorbent assays, flow cytometry, and polymerase chain reaction-based methods permit multiplexed and quantitative analyses that support stratified therapeutic choices. The proliferation of point-of-care platforms and rapid serological assays is altering outpatient decision pathways while digital health and artificial intelligence tools are beginning to assist in pattern recognition and risk stratification. Regulatory emphasis on clinical validity and utility, along with evolving reimbursement frameworks that reward diagnostic value, is reshaping product development strategies. Taken together, these shifts are fostering a more nuanced, evidence-driven approach to diagnosis that emphasizes earlier intervention and personalized management plans.

Assessment of 2025 US tariff policy impacts on diagnostic equipment, reagent supply chains, and operational procurement strategies affecting pediatric arthritis diagnostics

Tariff changes and trade measures implemented in the United States in 2025 have introduced notable implications for the procurement, production, and distribution of diagnostic equipment, reagents, and consumables that underpin juvenile idiopathic arthritis diagnostics. Increased duties on imported capital equipment and specialty reagents create pressure on laboratory operating budgets and can alter purchasing decisions for MRI scanners, ultrasound probes, and point-of-care devices. In response, healthcare providers and diagnostic vendors have begun reassessing supplier portfolios, prioritizing vendors with localized manufacturing or regional distribution capabilities to minimize exposure to import-related cost volatility.

Supply chain resilience has become a defining operational priority, prompting longer-term contracts with multiple suppliers, increased inventory buffers for critical reagents, and selective onshoring of manufacturing for high-value components. These adjustments have secondary effects on clinical adoption timetables, as procurement cycles extend and capital planning becomes more conservative. In parallel, some stakeholders are accelerating collaborations with domestic manufacturers and contract development organizations to safeguard continuity of novel assays and specialized consumables. Collectively, these dynamics signal a strategic pivot toward supply diversification and contractual flexibility that aims to preserve diagnostic quality while containing cost pressures arising from tariff policy changes.

Multidimensional segmentation insights revealing how product categories, technologies, end users, and test modalities interrelate to drive diagnostic selection and clinical integration

A granular view of segmentation illuminates how different diagnostic modalities and end users intersect to shape clinical pathways and commercial priorities. When evaluating by product type, distinctions between imaging diagnostics and laboratory diagnostics matter greatly; imaging diagnostics encompass MRI, ultrasound, and X-ray modalities that are critical for visualizing synovial inflammation and structural change, whereas laboratory diagnostics include biomarker tests, genetic tests, and serological tests that interrogate immune signatures and disease predisposition. Within biomarker tests, subcategories such as acute phase protein assays, autoantibody assays, and cytokine assays offer varying degrees of specificity and real-world clinical utility, influencing test selection based on clinical presentation and therapeutic intent.

Technology segmentation further clarifies performance trade-offs and workflow integration. Enzyme-linked immunosorbent assays remain a backbone for quantitative biomarker assessment, flow cytometry enables cellular phenotyping and immunophenotyping, and PCR-based technologies provide sensitive detection of genetic variants and pathogen-associated molecular signatures. End-user segmentation delineates operational contexts: diagnostic laboratories, hospitals, research laboratories, and specialty clinics each have distinct throughput, validation requirements, and integration capabilities that affect which platforms and assays are practical for routine use. Test-type considerations parse invasive approaches, including arthrocentesis and synovial biopsy, from noninvasive options such as blood tests and imaging procedures. Blood-based testing often leverages biomarker, genetic, and serological analyses, while imaging procedures emphasize MRI and ultrasound modalities. Understanding these layered segmentations is essential for aligning diagnostic development with clinical adoption pathways and laboratory capacities.

Region-specific diagnostic adoption patterns and operational priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and access

Regional dynamics significantly influence diagnostic practice patterns, regulatory interactions, and supply chain strategies across the three principal macro-regions. In the Americas, clinical adoption is shaped by a mix of advanced tertiary care centers and community hospitals that prioritize rapid, reimbursable diagnostics; this environment supports adoption of high-resolution imaging and validated biomarker assays, but also demands clear evidence of clinical utility to secure payer reimbursement. Transitional investments in point-of-care testing and telehealth are expanding access in underserved areas, while procurement sensitivity to cost pressures and tariff policy influences vendor selection and contract structuring.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure, regulatory frameworks, and reimbursement pathways leads to varied adoption rates for advanced diagnostics. High-capacity centers in western Europe frequently integrate molecular and imaging platforms into pediatric rheumatology care, whereas resource-constrained settings in other parts of the region often prioritize scalable, cost-effective laboratory assays and portable imaging solutions. Collaborative networks and clinician training programs are important mechanisms for elevating diagnostic standards across the region. Asia-Pacific exhibits rapid technology adoption driven by a large patient base, strong private sector investment, and active public health modernization efforts. Here, diverse regulatory landscapes and manufacturing capabilities create opportunities for local production of assays and devices, which can improve access and reduce dependency on long international supply chains. These regional nuances underscore the need for tailored market entry and deployment strategies that align clinical, regulatory, and operational realities.

How diagnostic innovators are leveraging platform differentiation, clinical partnerships, and integrated care solutions to accelerate adoption and clinical validation

Companies operating in the juvenile idiopathic arthritis diagnostic space are differentiating through a combination of platform innovation, clinical partnerships, and targeted go-to-market strategies. Diagnostic equipment manufacturers are extending service models and clinical support to accelerate adoption of imaging and point-of-care devices, while assay developers are emphasizing analytical robustness, multiplexing capability, and clinical validation to demonstrate utility in pediatric populations. Strategic collaborations between diagnostic firms and academic centers are accelerating biomarker discovery and the translation of research assays into validated clinical tests.

Commercial leaders are also developing modular solutions that integrate laboratory information systems, imaging outputs, and clinical decision support to create more seamless diagnostic workflows. Investment in regulatory strategy and payer engagement is becoming a competitive advantage, as firms that can demonstrate clinical pathways and cost-effectiveness gain preferential uptake in hospital systems and specialty clinics. In addition, contract research organizations and specialty laboratories are forming strategic alliances to support assay development, clinical validation, and post-market surveillance, enabling faster scale-up of novel tests while maintaining quality and compliance.

Actionable strategic priorities for diagnostic developers and healthcare leaders to enhance validation, supply resilience, integration, and payer alignment in pediatric rheumatology

Industry leaders should prioritize a set of practical actions to realize diagnostic improvements and to strengthen commercial positioning. First, invest in cross-disciplinary clinical validation studies that link biomarker and imaging readouts to treatment decisions and long-term outcomes, thereby demonstrating clinical utility and supporting reimbursement discussions. Second, build supply chain resilience by diversifying suppliers, pursuing localized manufacturing for critical reagents, and establishing contingency inventory strategies to mitigate import-related disruptions. Third, pursue strategic partnerships with pediatric rheumatology centers and reference laboratories to accelerate real-world evidence generation and to refine testing algorithms for different clinical settings.

Leaders should also focus on product interoperability and data integration, ensuring that assay outputs and imaging reports feed into electronic health records and decision support tools to streamline clinician workflows. Targeted education programs for primary care providers and referral networks will reduce diagnostic delay and increase appropriate test utilization. Finally, adopt adaptive pricing and contracting models that reflect the value delivered in specific care settings, while maintaining transparent dialogue with payers to align reimbursement pathways with demonstrated clinical benefits. Implementing these measures will enhance adoption, patient outcomes, and operational sustainability in diagnostic portfolios.

Transparent, mixed-methods research framework combining expert interviews, clinical literature synthesis, and technology assessments to underpin diagnostic insights and recommendations

This analysis synthesizes evidence from a structured research approach that combines primary stakeholder engagement with systematic secondary review to ensure rigor and relevance. Primary inputs included in-depth interviews with pediatric rheumatologists, laboratory directors, radiologists, and supply chain managers to capture clinical workflows, validation expectations, and procurement constraints. These qualitative insights were triangulated with a targeted review of peer-reviewed clinical literature, regulatory filings, and technology performance data to verify analytical assumptions and to contextualize clinical utility claims.

Technology assessments incorporated analytical performance metrics, sample throughput characteristics, and compatibility with routine laboratory infrastructure. Regulatory and reimbursement landscapes were examined through public guidance documents and payer policy statements to identify adoption barriers and enablers. Wherever possible, clinical validity findings were cross-checked against independent validation studies and consensus guidelines to ensure that recommendations reflect broadly accepted standards. The research process emphasized transparent documentation of sources, methodological limitations, and areas where further clinical evidence would materially improve diagnostic certainty.

Synthesis of diagnostic opportunities and operational imperatives that convert technological advances into measurable improvements in pediatric rheumatology care

In conclusion, diagnostic pathways for juvenile idiopathic arthritis are transitioning toward more precise, integrated, and patient-centered approaches driven by advances in imaging, biomarker science, and molecular diagnostics. These developments create opportunities to reduce diagnostic delay, to stratify patients for targeted therapies, and to improve long-term functional outcomes. However, successful implementation depends on coordinated clinical validation, robust supply chain strategies, and constructive payer engagement to ensure that new assays and platforms are adoptable across diverse care settings.

Operational resilience, data integration, and clinician education are essential complements to technological innovation; together, they convert diagnostic potential into measurable improvements in care. By aligning research, commercialization, and clinical adoption strategies, stakeholders can accelerate the translation of promising diagnostics into routine practice, ultimately improving detection, treatment selection, and monitoring for children affected by juvenile idiopathic arthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Juvenile Idiopathic Arthritis Diagnostic Market, by Product Type

  • 8.1. Imaging Diagnostics
    • 8.1.1. MRI
    • 8.1.2. Ultrasound
    • 8.1.3. X Ray
  • 8.2. Laboratory Diagnostics
    • 8.2.1. Biomarker Tests
      • 8.2.1.1. Acute Phase Protein Assays
      • 8.2.1.2. Autoantibody Assays
      • 8.2.1.3. Cytokine Assays
    • 8.2.2. Genetic Tests
    • 8.2.3. Serological Tests

9. Juvenile Idiopathic Arthritis Diagnostic Market, by Technology

  • 9.1. ELISA
  • 9.2. Flow Cytometry
  • 9.3. PCR Technology

10. Juvenile Idiopathic Arthritis Diagnostic Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Laboratories
  • 10.4. Specialty Clinics

11. Juvenile Idiopathic Arthritis Diagnostic Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Juvenile Idiopathic Arthritis Diagnostic Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Juvenile Idiopathic Arthritis Diagnostic Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Juvenile Idiopathic Arthritis Diagnostic Market

15. China Juvenile Idiopathic Arthritis Diagnostic Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Bio-Rad Laboratories, Inc.
  • 16.7. bioMerieux SA
  • 16.8. F. Hoffmann-La Roche AG
  • 16.9. Mayo Clinic
  • 16.10. Ortho Clinical Diagnostics Holdings plc
  • 16.11. QIAGEN N.V.
  • 16.12. Randox Laboratories Ltd
  • 16.13. Siemens Healthineers AG
  • 16.14. Sysmex Corporation
  • 16.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 132. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)